中国临床药理学杂志2018，Vol.34Issue(20)：2456-2460,5.DOI:10.13699/j.cnki.1001-6821.2018.20.018
新型胰高血糖素样肽-1类似物—索马鲁肽
A new glucagon-like peptide-1 analogues-Semaglutide
张新丽 1丁发明 2尹茂山2
作者信息
- 1. 青岛市黄岛区中心医院,山东 青岛266555
- 2. 国家食品药品监督管理总局 药品审评中心,北京 100022
- 折叠
摘要
Abstract
The glucagon-like peptide-1 (GLP-1) receptor agonist has been a well-received peptide product in the field of diabetes treatment .Semaglutide is a long-term GLP -1 agent, approved in December, 2017 by US Food and Drug Admins-tration(FDA).This article reviewed the pharmaceutical information , pharmacology and toxicology and clinical trial data of somaglutide , and commented on its efficacy and safety specially.We hope to provide reference for doctors and patients .关键词
索马鲁肽/2型糖尿病/胰高血糖素样肽1Key words
Semaglutide/type 2 diabetes mellitus/glucagon-like peptide-1分类
医药卫生引用本文复制引用
张新丽,丁发明,尹茂山..新型胰高血糖素样肽-1类似物—索马鲁肽[J].中国临床药理学杂志,2018,34(20):2456-2460,5.
